Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIB randomized double-blind placebo-controlled abatacept trial in psoriatic arthritis
2007-004241-15Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abatacept in psoriatic arthritis (PsA) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Investigator Global Assessment (IGA) clear or almost clear at Day 169 and Safety outcomes. Started Nov 2007; status: completed.
02
Drugs
abatacept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2007-004241-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004241-15.